HPTN 076 - Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278 LA, for Pre-Exposure Prophylaxis (PrEP)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Apr 2017
At a glance
- Drugs Rilpivirine (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections
- 22 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Feb 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.